{
  "ticker": "ADN",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975300",
  "id": "02975300",
  "pages": 6,
  "price_sensitive": false,
  "date": "20250731",
  "time": "1358",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250731/pdf/06mcwhjddqgry4.pdf",
  "summary": "- **Security Issuance**: 1,360,545 ordinary fully paid shares (ADN) issued on 30/07/2025.  \n- **Source**: Conversion of options (ADNAC) exercised on 25/07/2025 at zero cost (employee incentive scheme).  \n- **Post-Issuance Capital**:  \n  - **Quoted Ordinary Shares (ADN)**: 3,816,676,408.  \n  - **Outstanding Options/Performance Rights**: Highlights include 293.5m ADNO options, 338.4m ADNOC options, and 32.8m unquoted performance rights (ADNAB).  \n\n*No material trading or capital structure impact identified (small issuance, zero consideration, negligible dilution).*",
  "usage": {
    "prompt_tokens": 1580,
    "completion_tokens": 163,
    "total_tokens": 1743,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T04:28:10.610780"
}